SGLT-2 抑制剂对有或没有2型糖尿病患者的心脏自主功能的影响
Hasan Fehmi Özel1, Şüheda Alpay2, Emre Asker3
1Vocational School of Health Services, Manisa Celal Bayar University, Manisa, Türkiye.
Journal of diabetes and its complications
|March 30, 2025
概括
-葡萄糖共运输体-2 (SGLT-2) 抑制剂可以改善心率变化 (HRV),这是自主平衡的标志物,在2型糖尿病中. 需要进一步的研究来证实这些心血管益处.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体-2 (SGLT-2) 抑制剂已被确立为2型糖尿病 (T2DM) 和肥胖的治疗方法.
- 这些药物提供了超出血糖控制的好处,包括代谢改善和心血管风险降低.
- 通过心率变化 (HRV) 来评估心脏自主功能,对心血管健康至关重要.
研究的目的:
- 审查SGLT-2抑制剂在调节心脏自主功能的作用,重点关注HRV.
- 探索SGLT-2抑制剂影响自主平衡的机制.
- 评估SGLT-2抑制剂在管理自主功能障碍方面的现有证据和未来方向.
主要方法:
- 对SGLT-2抑制剂,T2DM,肥胖,心脏自主功能和HRV的现有文献的审查.
- 分析使用传统和先进HRV分析技术的研究.
- 检查建议的潜在机制,包括代谢,抗炎和抗氧化作用.
主要成果:
- SGLT-2 抑制剂可以改善代谢特征 (葡萄糖尿,尿,减肥),降低血压.
- 有证据表明,SGLT-2抑制剂可能会减弱交感过度活动,并增强副交感调制.
- 一些研究表明HRV参数的潜在改善 (例如,增加SDNN,RMSSD;减少LF/HF比率),但研究结果不一致.
结论:
- SGLT-2 抑制剂在积极影响心脏自主功能方面表现有前途,可能降低心血管事件风险.
- 进一步标准化,长期研究对于阐明机制和优化治疗策略至关重要.
- 研究涉及SGLT-2抑制剂的组合疗法可能会提高不同患者群体的心血管结果.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
813
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Dipeptidyl Peptidase 4 Inhibitors
876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Oral Hypoglycemic Agents: Glinides
821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
Oral Hypoglycemic Agents: Sulfonylureas
1.5K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
753
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
753


